Vinpocetine, cognition, and epilepsy.

Autor: Meador KJ; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: kmeador@stanford.edu., Leeman-Markowski B; Department of Neurology, New York University and VA New York Harbor Healthcare System, NY, NY USA. Electronic address: Beth.Leeman-Markowski@nyulangone.org., Medina AE; Department of Pediatrics, University of Maryland, Baltimore, MD, USA. Electronic address: amedinadejesus@som.umaryland.edu., Illamola SM; Department of Experimental & Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA. Electronic address: sillamol@umn.edu., Seliger J; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: jseliger@stanford.edu., Novak G; Department of Neurology, Emory University, Atlanta, GA, USA. Electronic address: gnovak2@emory.edu., Lin C; School of Medicine, University of California, San Diego, CA, USA. Electronic address: christinelin@ucsd.edu., Ivanisevic M; Department of Psychology, VA Boston Healthcare System, Boston, MA, USA., Razavi B; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: Brazavi@stanford.edu., Marino S; Department of Experimental & Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA. Electronic address: marin007@umn.edu., Boyd A; CNS Vital Signs, NC, USA. Electronic address: aboyd@cnsvs.com., Loring DW; Department of Neurology, Emory University, Atlanta, GA, USA. Electronic address: dloring@emory.edu.
Jazyk: angličtina
Zdroj: Epilepsy & behavior : E&B [Epilepsy Behav] 2021 Jun; Vol. 119, pp. 107988. Date of Electronic Publication: 2021 May 03.
DOI: 10.1016/j.yebeh.2021.107988
Abstrakt: Objective: Vinpocetine has been shown to enhance memory in animal models, with possible cognitive benefit in humans. The present study sought to demonstrate if vinpocetine can enhance cognition in healthy volunteers or patients with epilepsy. In addition, we compare blood levels of vinpocetine and its active metabolite (apovincaminic acid; AVA) in humans and animals to further characterize factors related to possible therapeutic benefit.
Methods: The cognitive effects of vinpocetine were assessed in healthy adult volunteers (n = 8) using a double-blind, randomized, crossover design at single doses (placebo, 10, 20, and 60 mg oral). Cognitive effects of vinpocetine in patients with focal epilepsy (n = 8) were tested using a double-blind, randomized, crossover design at single doses (placebo, 20 mg oral) followed by one-month open label at 20 mg oral three times a day. The neuropsychological battery included both computerized and non-computerized tests. Levels of vinpocetine and AVA in the human studies were compared to levels in 45 mice across time dosed at 5-20 mg/kg intraperitoneal of vinpocetine.
Results: No significant cognitive benefits were seen in healthy volunteers or patients with epilepsy. No appreciable side effects occurred. Vinpocetine and AVA levels were lower in humans than animals.
Conclusions: Vinpocetine was well tolerated, but was not associated with positive cognitive effects. However, blood levels obtained in humans were substantially less than levels in animals obtained from dosages known to be effective in one model. This suggests that higher dosages are needed in humans to assess vinpocetine's cognitive efficacy.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: